There was a significant increase in the frequency of RUNX1 mutations towards progression/transformation of CMML into AML but no increase in the prevalence of mutations of SETBP1, TET2, EZH2, ASXL1, SRSF2, and TP53. This evidence concerns the gene TP53 and chronic myelomonocytic leukemia.